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Abstract
Background Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported
adverse event in AD clinical trials with dupilumab.
Objective To survey opinions and experience about conjunctivitis occurring in AD, including those during dupilumab
treatment in a group of AD experts from the International Eczema Council (IEC).
Methods Electronic survey and in-person discussion of management strategies.
Results Forty-six (53.5%) IEC members from 19 countries responded to the survey. Consensus was reached
for several statements regarding diagnostic workup, referral and treatment. IEC members suggest that patients
with AD should (i) routinely be asked about ocular complaints or symptoms, (ii) obtain information about the
potential for conjunctivitis before starting dupilumab therapy and (iii) if indicated, be treated with dupilumab
despite previous or current conjunctivitis. In cases of new-onset conjunctivitis, there was consensus that dupi-
lumab treatment should be continued when possible, with appropriate referral to an ophthalmologist.
Limitations The study relies on expert opinion from dermatologists. Responses from few dermatologists without dupi-
lumab access were not excluded from the survey.
†Correction added on 29 June 2019, after first online publication: the surname of author ‘C. Traidl-Hoffmann’ has been corrected.
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Conclusion The IEC recommends that dermatologists address conjunctivitis in patients with AD, especially during
treatment with dupilumab.
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Introduction
Atopic dermatitis (AD) is a chronic inflammatory skin condi-
tion.1 Patients with AD have an increased risk of developing ker-
atoconus, cataract, glaucoma and blepharitis, as well as allergic,
atopic, vernal and infectious (kerato) conjunctivitis.2,3
Clinical trials with dupilumab, a monoclonal antibody that
inhibits interleukin (IL)-4 and IL-13 signalling, have demon-
strated efficacy in moderate-to-severe AD. However, trials have
also shown an increased incidence of conjunctivitis with dupilu-
mab treatment,4–6 which in some cases leads to cessation of
treatment.7 The clinical features of dupilumab-associated con-
junctivitis include bilateral inflammation of the anterior con-
junctiva and hyperaemia of the limbus, which may cause
nodular swelling.8 In a case series, dupilumab-associated con-
junctivitis appeared to occur more often in patients with severe
AD at baseline and with atopic comorbidities. At present, how-
ever, predictive factors are unknown.7
There is no literature-based guidance available about manage-
ment of dupilumab-associated conjunctivitis. A group of AD
experts, all councillors or associates of the International Eczema
Council (IEC), therefore addressed this issue by completing a
survey and discussing conjunctivitis and its management in
patients with AD.
Materials and methods
The IEC consists of 86 AD experts from 22 countries (http://
www.eczemacouncil.org/). In May 2018, a survey developed
by three of the authors (J.P.T, M.S.d.B.W. and A.W.) was sent
electronically to IEC councillors and associates to examine
their opinions regarding management of conjunctivitis in
patients with AD focusing on dupilumab-associated conjunc-
tivitis. The survey consisted of questions and statements fol-
lowed by possible responses of ‘strongly disagree’, ‘disagree’,
‘neither agree, nor disagree’, ‘agree’ and ‘strongly agree’ as well
as closed response categories (for detailed questions, Table 1).
All responses were anonymous. No a priori definition of con-
sensus was determined but, post hoc, and it was decided to
use rules similar to the Harmonizing Outcome Measures for
Eczema (HOME) initiative, which have been used in previous
IEC consensus articles.9,10 Consensus required that less than
30% of the voters disagreed (i.e. no more than 30% had to
mark the following responses ‘strongly disagreed’ or ‘dis-
agreed’) for each question with a response rate of at least 90%
of respondents in the survey. Descriptive data analysis was
performed using Excel (Windows). On 13 September 2018, a
round table discussion among IEC members was held on the
topic at the European Academy of Dermatology and Venereol-
ogy meeting in Paris, France. In the remainder of this
manuscript, IEC members who completed the survey are
respondents; IEC members who participated in the discussion
participants.
Results
Survey results
The following sections highlight key findings from the survey.
Question and response details are shown in Table 1.
Respondent characteristics
A total of 46 councillors and associates from six continents
responded to the survey (participation rate 53.5%). Respondents
came from Germany (n = 8), the United States (n = 7), the
Netherlands (n = 4), United Kingdom (n = 4), Denmark
(n = 3), France (n = 3), Korea (n = 2), Japan (n = 2), Australia
(n = 2) and Canada (n = 2), as well as, Brazil, China, India, Ire-
land, Israel, Italy, Switzerland, Taiwan and Tanzania (each
n = 1).
A total of 38% and 22% of respondents reported seeing 0–20
paediatric and adult patients with AD per week, respectively,
whereas 27% and 31% of respondents reported seeing 21–40
paediatric and adults patients with AD per week, respectively.
The proportion of respondents that reported seeing 41–100 pae-
diatric and adult patients per week was 31% and 33%, respec-
tively. Remaining respondents reported seeing more than 100
paediatric and adult patients with AD per week.
Dermatologist-estimated frequency of ocular surface
disease and diagnostic workup
Respondents reported relatively frequent occurrence of conjunc-
tivitis and blepharitis in their patients with AD (Fig. 1a and b).
As an indication of disease severity, half of the respondents
reported having seen a paediatric or adult AD patient who
required corneal transplant. Consensus was reached that patients
with AD routinely should be asked about ocular complaints or
symptoms, and in case of conjunctivitis, routinely referred to an
ophthalmologist for diagnostic workup and treatment. Consen-
sus was reached that AD patients with conjunctivitis should
undergo (or be referred to) skin prick or specific IgE testing for
common aeroallergen and be referred for patch testing with
an ophthalmological series and native eye drops and ointments
to detect possible delayed-type hypersensitivity to topical
ingredients.
Treatment
Consensus was reached that dermatologists should initiate rele-
vant treatment with eye drops/ointment, or oral antihistamines,
for conjunctivitis before referring to an ophthalmologist, but
also dermatologists should leave the indication to use of corti-
costeroid, ciclosporin or tacrolimus eye drops for conjunctivitis
to ophthalmologists. Consensus was reached that patients with
AD should be informed about possible conjunctivitis before pre-
scribing dupilumab. There was also consensus that previous,
(kerato) conjunctivitis in patients with AD should not prevent
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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the use of dupilumab (Fig. 2; for discussion on dupilumab treat-
ment initiation in patients with current conjunctivitis, see
detailed discussion below). There was consensus that patients
with new-onset conjunctivitis during dupilumab treatment
should always be referred to an ophthalmologist, but also that
dupilumab treatment should be continued while awaiting oph-
thalmologist consultation.
Round table discussion
The survey results were presented at the meeting in Paris where
20 councillors and associates were present. Most of the
discussion concerned dupilumab-associated conjunctivitis,
which most IEC members had seen and treated in their adult
patients with AD. Dupilumab-associated conjunctivitis had also
been seen in paediatric patients treated in clinical trials with
dupilumab. It was agreed that secondary analyses of completed
clinical trials with dupilumab and ongoing postmarketing reg-
istries are urgently needed to identify sub-groups with increased
risk of conjunctivitis after dupilumab administration. Better
understanding of the aetiopathogenesis of dupilumab-associated
conjunctivitis to identify susceptible patients and future treat-
ments was emphasized. Although conjunctivitis has been
Table 1 Overview of responses given by IEC members in a survey about conjunctivitis. Statements that reached consensus are high-
lighted with grey. Consensus required that less than 30% of the voters disagreed (i.e. no more than 30% had to mark the following
responses ‘strongly disagreed’ or ‘disagreed’) for each question with a response rate of at least 90% of the respondents.
Survey Questions Strongly
agree
Agree Neither
agree nor
disagree
Disagree Strongly
disagree
% n % n % n % n % n
Atopic dermatitis patients should routinely be asked about ocular complaints or
symptoms
55.81 24 32.56 14 9.30 4 2.33 1 0.00 0
I have observed corneal transplant in one or several of my atopic dermatitis patients
where I assume it was due to excessive rubbing (both children and adults)
15.91 7 34.09 15 15.91 7 22.73 10 11.36 5
Atopic dermatitis patients with conjunctivitis should routinely be referred to an
ophthalmologist for diagnostic work-up and treatment
23.26 10 53.49 23 9.30 4 13.95 6 0.00 0
Dermatologists should initiate relevant treatment with eye drops/eye ointment or oral
antihistamines for conjunctivitis themselves before referring to an ophthalmologist
6.82 3 40.91 18 31.82 14 18.18 8 2.27 1
Atopic dermatitis patients with conjunctivitis should undergo (or be referred to) skin
prick testing (or specific IgE) for common aeroallergens
25.58 11 25.58 11 30.23 13 16.28 7 2.33 1
Atopic dermatitis patients with conjunctivitis should undergo (or be referred to) skin
prick testing to eyedrops if such are used
9.09 4 25.00 11 25.00 11 38.64 17 2.27 1
Atopic dermatitis patients with conjunctivitis should undergo (or be referred to) patch
testing with a standardized ophthalmologic series, and native eye drops/ointments to
diagnose possible delayed type hypersensitivity reactions to topical ingredients if
these are used
9.30 4 41.86 18 23.26 10 25.58 11 0.00 0
Dermatologists should leave the indication to use of ciclosporin or tacrolimus eye
drops for conjunctivitis to ophthalmologists
18.18 8 36.36 16 25.00 11 18.18 8 2.27 1
Dermatologists should leave the indication to use of corticosteroid eye drops for
conjunctivitis to ophthalmologists
15.91 7 38.64 17 18.18 8 25.00 11 2.27 1
It is important to routinely inform about possible conjunctivitis in your atopic
dermatitis patients before prescribing dupilumab (Dupixent)
59.09 26 31.82 14 6.82 3 2.27 1 0.00 0
Patients with atopic dermatitis should be referred to an ophthalmologist before
initiation of dupilumab therapy
4.88 2 14.63 6 14.63 6 56.10 23 9.76 4
The risk of conjunctivitis when using dupilumab may prevent me from using the drug
in patients with previous (kerato-) conjunctivitis?
4.55 2 13.64 6 22.73 10 47.73 21 11.36 5
The risk of conjunctivitis when using dupilumab may prevent me from using the drug
in patients with current (kerato-) conjunctivitis?
4.65 2 41.86 18 25.58 11 23.26 10 4.65 2
Patients with new onset conjunctivitis during dupilumab treatment should always be
referred to an ophthalmologist
20.45 9 47.73 21 20.45 9 11.36 5 0.00 0
Patients with new onset conjunctivitis during dupilumab treatment should be referred
to an ophthalmologist in more severe cases, (inadequate response to artificial tears
and/or antihistamine eye drops)
50.00 22 34.09 15 6.82 3 9.09 4 0.00 0
New onset conjunctivitis during dupilumab should result in referral of the patient to
an ophthalmologist but treatment should be continued
11.36 5 56.82 25 25.00 11 6.82 3 0.00 0
New onset conjunctivitis during dupilumab should result in referral of the patient to
an ophthalmologist but treatment should be paused
4.55 2 4.55 2 31.82 14 52.27 23 6.82 3
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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associated with the experimental use of IL-13 inhibitors for AD,
the numbers in trials to date are small and discussants warned
about the possibility of similar ocular complications in AD
patients treated with IL-13 inhibitors.
It was the experience of IEC members that many AD patients
with dupilumab-associated conjunctivitis clear their ocular
symptoms, some spontaneously and some after a short course of
treatment with lubricating eye drops and ointments containing
corticosteroids or tacrolimus. Several IEC members had good
experiences with the use of fluorometholone 0.1% eye drops or
tacrolimus 0.03% ointment.8 Corticosteroid eye drops should be
used with caution, since they increase the risk of superinfection
and glaucoma. Nevertheless, few patients stop dupilumab treat-
ment due to conjunctivitis and conjunctivitis may improve dra-
matically during dupilumab use. These varied observations
regarding course further stress the need to study these patients
and find correlates with outcome. Some IEC members recom-
mended artificial lubricating tears when starting a patient on
dupilumab as prevention to reduce ocular complaints and the
risk of conjunctivitis but, while there is a scientific rationale for
this intervention, more work is needed to develop optimal regi-
mens and assess its efficacy. A strategy pursued by some IEC
members is to taper dupilumab injections e.g. to every 3rd week,
but potential correlation with extending the dosing interval and
increasing the risk of developing anti-drug antibodies against
dupilumab was stressed.
The clinical course and prognosis of already existing conjunc-
tivitis following initiation of dupilumab is difficult to predict. In
the experience of IEC councillors, some patients with AD may
experience worsening of ocular symptoms due to unrecognized
effects of dupilumab treatment, some may experience stable and
unchanged conjunctivitis, and some may experience improve-
ment and even complete resolution of ocular symptoms.
Patients should be informed about the potential of conjunctivitis
with dupilumab and should be referred to an ophthalmological
when clinically indicated. It was stressed that at this moment
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Figure 1 Proportion of IEC member who report having seen pediatric (a) and adult (b) patients with AD and who have been diagnosed
with conjunctivitis and blepharitis within the 7 past 12 months.
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there are also no reliable data on the course of atopic keratocon-
junctivitis and vernal keratoconjunctivitis during dupilumab
treatment. Patient experiencing these should be carefully moni-
tored by an ophthalmologist before and during treatment with
dupilumab. The AD severity, conjunctivitis severity, possible con-
traindications, possible effect of dupilumab therapy on concomi-
tant asthma or other comorbidities, as well as other treatment
options, should be considered on an individual patient basis.
Discussion
This survey of IEC councillors and associates, representing 19
countries from six continents, examined opinions regarding
proper management of paediatric and adult patients with AD
with conjunctivitis, and in particular, conjunctivitis occurring
during dupilumab treatment. Participants in this study care for
many patients with AD weekly.
Few studies have examined the exact prevalence and incidence
of conjunctivitis in patients with AD. In young children from a
U.S. trial, the prevalence of allergic conjunctivitis was 16%,11
whereas chronic conjunctivitis and superficial keratitis were
observed in 32% and 7% of 44 adult patients with AD when
examined ophthalmologically.12 In Danish adults, 12% and 18%
of adults with mild and severe AD, respectively, had used anti-
inflammatory ocular agents, and 13 of 1000 severe patients with
AD per year had used an ocular anti-inflammatory agent com-
pared with 6 of 1000 individuals (sex- and age-adjusted) from
the general population.3 These data emphasize that conjunctivi-
tis is more common in patients with AD than controls and,
accordingly, the IEC reached consensus and recommended that
patients with AD routinely should be asked about signs and
symptoms of conjunctivitis. Recommendations about eye exami-
nation for conjunctivitis in AD, as well as diagnostic workup,
referral and proper management, have not been included in
recent European and North American guidelines for AD.1,13–18
The estimated prevalence of ocular surface disease provided
by the IEC members should be interpreted with caution because
of the risk of recall bias and the skewed population towards
more severe disease seen by IEC members. Moreover, there was
no information about the severity or accuracy of diagnosis of the
conjunctivitis (e.g. if ophthalmologist-confirmed). Nonetheless,
IEC members experienced that adults with AD frequently suffer
from conjunctivitis and blepharitis. It is currently unclear
whether blepharitis should be regarded as part of AD or, instead,
occurs as a result of co-pathogenic factors and is a complication
or comorbidity. Importantly, other aetiologies of blepharitis, e.g.
allergic contact dermatitis, or infestation with demodex mites,
should also be considered in patients with AD. Sometimes, aeti-
ological classification of conjunctivitis is straightforward, e.g.
onset of allergic rhinoconjunctivitis during pollen season in AD
patients with known allergic disease and positive response to
antihistamines, or purulent infectious conjunctivitis in conjunc-
tion with impetiginized AD, a positive culture, and a favourable
response to antibiotics. At other times, it can be clinically diffi-
cult to categorize conjunctivitis and, in this case, more extensive
diagnostic workup is required. There was consensus to recom-
mend pursuit of a diagnostic workup for type 1 and 4 allergy in
AD patients with conjunctivitis. Notably, in severe conjunctivitis
cases, it is important that an ophthalmologist rule out atopic
keratoconjunctivitis, which may lead to keratitis and blind-
ness.2,19
Strongly agree
Agree
Neither agree nor disagree
Disagree
The risk of conjunctivitis when using dupilumab 
may prevent me from using the drug in patients 
with current (kerato-) conjunctivitis?
The risk of conjunctivitis when using dupilumab 
may prevent me from using the drug in patients 
with previous (kerato-) conjunctivitis?
Patients with new onset conjunctivitis 
during dupilumab treatment should 
always be referred to an ophthalmologist
41.86%
13.64%
22.73%
25.58%
23.26%
4.65% 4.65% 4.55%
47.73%
11.36%11.36%
20.45%
20.45%
47.73%
Strongly disagree
Figure 2 Key findings from the survey regarding management of AD patients with conjunctivitis treated with dupilumab.
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There was consensus that dermatologists should prescribe
lubricating eye drops, ointments or oral antihistamines in AD
patients with conjunctivitis, but also that dermatologists should
leave the use of corticosteroid, ciclosporin or tacrolimus eye
drops to ophthalmologists. A general concern with corticos-
teroid eye drop use, besides the risk of superinfection, is induc-
tion of increased ocular pressure, which may result in glaucoma.
The price of commercially available ciclosporin eyedrop treat-
ment is relatively high and may limit its use, but ciclosporin eye
drops are generally well tolerated and are effective for vernal and
atopic keratoconjunctivitis.20 Compounding of ciclosporin eye-
drops in a pharmacy may be an alternative, if available. The use
of tacrolimus eye drops (and tacrolimus as ointment) has also
proven favourable with no systemic side-effects in a large trial;
however, incident herpetic and bacterial infections can occur,
warranting ophthalmological monitoring.21 Despite the more
limited experience with eye drops by dermatologists, rapid access
to ophthalmological service may be difficult, sometimes war-
ranting a short course of corticosteroid eye drop without oph-
thalmological consultations. However, persistent or recurrent
conjunctivitis requiring repeated or prolonged use of corticos-
teroid, tacrolimus and ciclosporin containing eye drops, must be
managed by an ophthalmologist, given the risk of glaucoma, cat-
aract and infections.
Conjunctivitis occurring during dupilumab treatment is
observed in 9–28% of every 2-week dupilumab users in clinical
trials4–6 and in real-world evidence from US, Dutch and French
registries (oral presentations, EADV, Paris, September, 2018).7
Observations in other clinical trials may aid in understanding
the pathogenesis of conjunctivitis occurring during dupilumab
treatment. For example, the risk of conjunctivitis in patients
with asthma receiving treatment with dupilumab is similar to
that of controls,22 raising the question of ocular or immune dif-
ferences between patients with AD and asthma. Furthermore,
larger trials of IL-13 inhibitors may indicate the role of IL-13
inhibition directly vs. IL-4 inhibition or the combination
through IL4Ra targeting; in small phase II trials, an increased
incidence of conjunctivitis was observed with lebrikizumab, but
not tralokinumab.23,24 One possible mechanism of conjunctivitis
occurring during dupilumab treatment involves the observed
early increases in blood total eosinophil counts, since eosinophil
chemotactic and activating peptides, eotaxin 1 and 2, are
increased in the mucus and tears of patients with vernal and ato-
pic keratoconjunctivitis.25 Other hypotheses include a patho-
genic role of increased OX40 ligand activity,26 or IL-17 driven
inflammation following colonization with demodex mites.27
Notably, a recent histopathology case study showed marked
depletion of goblet cells in conjunctivae of patients with dupilu-
mab-associated conjunctivitis.28
The limitations of our study include the following: 1) reliance
on expert dermatologist opinion; 2) while discussion partici-
pants were all dermatologists experienced with dupilumab use
(and managing dupilumab-associated conjunctivitis) from clini-
cal trials and dermatology office use; number of respondents was
relatively small; and survey respondents included few councillors
from countries lacking access to dupilumab.
Conclusion
This small IEC member survey and round table discussion
provided guidance from a group of AD experts regarding gen-
eral diagnostic workup and management of conjunctivitis
occurring during dupilumab treatment. We achieved consensus
for several statements regarding management of conjunctivitis
in patients with AD, also before and during dupilumab ther-
apy, but emphasize that correct classification and treatment of
conjunctivitis is important and that the threshold of contacting
ophthalmologists should be low. Topical ophthalmological
therapies recommended by IEC members have proved success-
ful and have allowed dupilumab treatment continuation, but
consideration of alternative diagnoses that require further
assessment and/or initiation of treatment other than topical
anti-inflammatory medication is critical before initiation of
therapy29; these management decisions may be beyond the
ability and comfort of a dermatologist or other dupilumab
prescriber and may require joint management with an oph-
thalmologist. Future studies on the aetiopathogenesis, predic-
tive factors and approach to conjunctivitis occurring during
dupilumab treatment are warranted.
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